 | • レポートコード：MRC2301A044 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、240ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：バイオ |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートでは、2021年に120.9億ドルであった世界のXXX市場規模が、2022年に148.5億ドルに到達し、2027年まで年平均22.98%で成長して418.4億ドルまで拡大すると予測しています。本レポートは、XXXの世界市場について総合的・多面的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（NGSデータ分析・保存・管理、NGSプラットフォーム・消耗品・サービス、プレシーケンシング）分析、技術別（ターゲットシーケンシング・リシーケンシング、全エクソームシーケンシング、全ゲノムシーケンシング）分析、用途別（農業、バイオマーカー発見、診断、創薬、精密医療）分析、エンドユーザー別（学術・研究機関、感染症、製薬・バイオテクノロジー企業）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などを以下の構成でまとめております。本資料には、10x Genomics、Agilent Technologies, Inc.、Beijing Genomics Co. Ltd.、Beijing Genomics Institute (BGI)、Bio-Rad Laboratories, Inc.、BioMerieux S.A.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の次世代シーケンシング（NGS）市場規模：種類別 - NGSデータ分析・保存・管理における市場規模 - NGSプラットフォーム・消耗品・サービスにおける市場規模 - プレシーケンシングにおける市場規模 ・世界の次世代シーケンシング（NGS）市場規模：技術別 - ターゲットシーケンシング・リシーケンシングの市場規模 - 全エクソームシーケンシングの市場規模 - 全ゲノムシーケンシングの市場規模 ・世界の次世代シーケンシング（NGS）市場規模：用途別 - 農業における市場規模 - バイオマーカー発見における市場規模 - 診断における市場規模 - 創薬における市場規模 - 精密医療における市場規模 ・世界の次世代シーケンシング（NGS）市場規模：エンドユーザー別 - 学術・研究機関における市場規模 - 感染症における市場規模 - 製薬・バイオテクノロジー企業における市場規模 ・世界の次世代シーケンシング（NGS）市場規模：地域別 - 南北アメリカの次世代シーケンシング（NGS）市場規模 アメリカの次世代シーケンシング（NGS）市場規模 カナダの次世代シーケンシング（NGS）市場規模 ブラジルの次世代シーケンシング（NGS）市場規模 … - アジア太平洋の次世代シーケンシング（NGS）市場規模 中国の次世代シーケンシング（NGS）市場規模 インドの次世代シーケンシング（NGS）市場規模 韓国の次世代シーケンシング（NGS）市場規模 台湾の次世代シーケンシング（NGS）市場規模 … - ヨーロッパ/中東/アフリカの次世代シーケンシング（NGS）市場規模 イギリスの次世代シーケンシング（NGS）市場規模 ドイツの次世代シーケンシング（NGS）市場規模 フランスの次世代シーケンシング（NGS）市場規模 ロシアの次世代シーケンシング（NGS）市場規模 … - その他地域の次世代シーケンシング（NGS）市場規模 ・競争状況 ・企業情報 |
The Global Next Generation Sequencing Market size was estimated at USD 12.09 billion in 2021 and expected to reach USD 14.85 billion in 2022, and is projected to grow at a CAGR 22.98% to reach USD 41.84 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Next Generation Sequencing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across NGS Data Analysis, Storage, & Management, NGS Platforms, Consumables, & Services, and Pre-sequencing.
Based on Technology, the market was studied across Targeted Sequencing & Re-sequencing, Whole Exome Sequencing, and Whole Genome Sequencing.
Based on Application, the market was studied across Agriculture, Biomarker Discovery, Diagnostics, Drug Discovery, and Precision Medicine.
Based on End User, the market was studied across Academic & Research Institutes, Infectious Diseases, and Pharmaceutical & Biotechnology Companies.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Next Generation Sequencing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Next Generation Sequencing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Next Generation Sequencing Market, including 10x Genomics, Agilent Technologies, Inc., Beijing Genomics Co. Ltd., Beijing Genomics Institute (BGI), Bio-Rad Laboratories, Inc., BioMerieux S.A., Charles River Laboratories, Inc., DNASTAR, Inc, Eurofins Scientific, F. Hoffmann-La Roche AG, Gatc Biotech AG, Genomatix GmbH, Genome Life Sciences, GenScript Biotech Corporation, Illumina, Inc., Macrogen, Inc., NanoString Technologies, Inc., Oxford Nanopore Technologies, Ltd., Pacific Biosciences of California, Inc., Partek, Inc., Perkin Elmer, Inc., PierianDx, Inc., Qiagen N.V., Saphetor SA, Takara Bio Inc., Thermo Fisher Scientific, Inc., Xcelris Genomics, Ltd, and Zymo Research.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Next Generation Sequencing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Next Generation Sequencing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Next Generation Sequencing Market?
4. What is the competitive strategic window for opportunities in the Global Next Generation Sequencing Market?
5. What are the technology trends and regulatory frameworks in the Global Next Generation Sequencing Market?
6. What is the market share of the leading vendors in the Global Next Generation Sequencing Market?
7. What modes and strategic moves are considered suitable for entering the Global Next Generation Sequencing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing need of inexpensive sequencing devices in routine medical checkups and clinical settings
5.1.1.2. Need for operator independent accuracy and minimal hands-on time
5.1.1.3. Transformation of clinical microbiology and public health laboratories
5.1.1.4. Need to develop the single workflow for cancer research, human identification applications, inherited disease research, and infectious disease research
5.1.2. Restraints
5.1.2.1. Huge data processing and reimbursement uncertainty in clinical settings
5.1.2.2. Limited supplementary standards and guidance for NGS applications
5.1.2.3. Lack of skilled professionals
5.1.3. Opportunities
5.1.3.1. Potential significance of NGS analysis in identifying cancer mutations
5.1.3.2. Investigative NGS use to enable single-cell genomics
5.1.3.3. Service providers offering the cloud-based alternative to in-house platforms
5.1.3.4. High degree of collaboration and M&A activity in market space
5.1.4. Challenges
5.1.4.1. High library prep costs
5.1.4.2. Security and privacy of concerns for NGS Data
5.1.4.3. Data analysis and bioinformatics challenges
5.2. Cumulative Impact of COVID-19
6. Next Generation Sequencing Market, by Type
6.1. Introduction
6.2. NGS Data Analysis, Storage, & Management
6.3. NGS Platforms, Consumables, & Services
6.4. Pre-sequencing
7. Next Generation Sequencing Market, by Technology
7.1. Introduction
7.2. Targeted Sequencing & Re-sequencing
7.3. Whole Exome Sequencing
7.4. Whole Genome Sequencing
8. Next Generation Sequencing Market, by Application
8.1. Introduction
8.2. Agriculture
8.3. Biomarker Discovery
8.4. Diagnostics
8.5. Drug Discovery
8.6. Precision Medicine
9. Next Generation Sequencing Market, by End User
9.1. Introduction
9.2. Academic & Research Institutes
9.3. Infectious Diseases
9.4. Pharmaceutical & Biotechnology Companies
10. Americas Next Generation Sequencing Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Next Generation Sequencing Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Next Generation Sequencing Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. 10x Genomics
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. Agilent Technologies, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Beijing Genomics Co. Ltd.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Beijing Genomics Institute (BGI)
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. Bio-Rad Laboratories, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. BioMerieux S.A.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Charles River Laboratories, Inc.
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. DNASTAR, Inc
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. Eurofins Scientific
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. F. Hoffmann-La Roche AG
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Gatc Biotech AG
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Genomatix GmbH
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Genome Life Sciences
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. GenScript Biotech Corporation
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Illumina, Inc.
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Macrogen, Inc.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. NanoString Technologies, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Oxford Nanopore Technologies, Ltd.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Pacific Biosciences of California, Inc.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Partek, Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. Perkin Elmer, Inc.
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. PierianDx, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. Qiagen N.V.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Saphetor SA
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Takara Bio Inc.
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. Thermo Fisher Scientific, Inc.
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
14.27. Xcelris Genomics, Ltd
14.27.1. Business Overview
14.27.2. Key Executives
14.27.3. Product & Services
14.28. Zymo Research
14.28.1. Business Overview
14.28.2. Key Executives
14.28.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing